Hypothyroidism

Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis

Retrieved on: 
Mercredi, mars 9, 2022
Lists of diseases, Insilico Medicine, Library, Phenotype, Lysosome, Kidney, UZH, Gonad, University, Hypogonadism, Kidney disease, Mechanism, Risk, Pancreas, CTNS, Research, Public health, Therapy, FDA, AI, Artificial intelligence, Cancer, Cystinosis, Cystine, Tissue, Quality of life, Fanconi syndrome, Diabetes, CNS, CKD, Glycogen storage disease, Chemistry, NEW, MD, Metabolism, Brain, Cysteamine, Patient, Epithelium, Muscle, Central nervous system, Omics, Solution, Zebrafish, Biology, Knowledge, Chronic kidney disease, Fibrosis, Immunity, Disease, Myopathy, Intelligence, Hypothyroidism, CEO, Liver, Pharmaceutical industry, Medical device, In silico

NEW YORK and ZURICH, March 9, 2022 /PRNewswire/ -- The MIKADO group, a translational team at the UZH focused on generating evidence-driven insights to understand and treat rare inherited kidney diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI)-driven drug discovery company, today announced a research and development collaboration designed to accelerate the discovery of transformative novel therapeutics for cystinosis. The duration of the initial research collaboration will be one year.

Key Points: 
  • Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain.
  • - The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis.
  • The duration of the initial research collaboration will be one year.
  • Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis

Retrieved on: 
Mercredi, mars 9, 2022
Insilico Medicine, Library, Phenotype, Lysosome, Kidney, UZH, Hypogonadism, Kidney disease, Pancreas, Research, CTNS, Public health, Therapy, FDA, AI, Artificial intelligence, Cancer, Cystinosis, Cystine, Tissue, Diabetes, Quality of life, Fanconi syndrome, CNS, CKD, Glycogen storage disease, Chemistry, MD, Multimedia, Metabolism, Brain, Cysteamine, Patient, Epithelium, Muscle, Central nervous system, Omics, Solution, Zebrafish, Biology, Knowledge, Chronic kidney disease, Fibrosis, Immunity, Disease, Myopathy, Intelligence, Hypothyroidism, Lists of diseases, CEO, Liver, Pharmaceutical industry, Medical device, In silico

"I am thrilled by the collaboration between MIKADO and Insilico.

Key Points: 
  • "I am thrilled by the collaboration between MIKADO and Insilico.
  • We are pleased to partner with MIKADO at the UZH combining the best of PandaOmics target discovery AI and human intelligence for the potential benefit of cystinosis patients worldwide," said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.
  • Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

Cancer Biologics Global Market Research Report 2021: Long-term Forecast to 2025 & 2030 Featuring Major Players - AbbVie, Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Co, and Amgen - ResearchAndMarkets.com

Retrieved on: 
Mercredi, décembre 15, 2021
Biotechnology, Health, Oncology, Colon, AbbVie, Diarrhea, China Biologic Products, GlaxoSmithKline, Allergy, Hoffmann-La Roche, Melanoma, FDA, Protein, Conditional sentence, Bladder cancer, Company, Endometrial cancer, Physician, Cancer, Eli Lilly and Company, Amgen, NCBI, Prostate cancer, Biomarker, Hypothyroidism, COVID-19, Time, Breast cancer, Kidney, Historic Market Place, Hildesheim, Non-Hodgkin lymphoma, Lung, GI, Death, Biotechnology, Mouth, Safety, Patient, Growth, Hepatitis, World Health Organization, Prevalence, WHO, Leukemia, Thyroid cancer, Disability, Liver cancer, Pancreatic cancer, Skin, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Medical imaging

The "Cancer biologics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer biologics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, and Amgen Inc.
  • The cancer biologics market consists of sales of cancer biologics.
  • The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics.

Global Thyroid Function Tests Devices Pipeline Product Market Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Lundi, décembre 6, 2021
Biotechnology, Health, Medical Devices, Thyroid, Non-functional testing, Hyperthyroidism, Thyroid function tests, Thyroid hormones, Hypothyroidism, Pharmaceutical industry

The "Thyroid Function Tests - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Function Tests - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive information about the Thyroid Function Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Thyroid Function Tests (TFTs) are performed to evaluate the function of thyroid gland.
  • Abnormal level of thyroid hormones in the body can cause either hyperthyroidism (high level of thyroid hormones) or hypothyroidism (low level of thyroid hormones).

Global Endocrine Testing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Mercredi, décembre 1, 2021
Health, General Health, Patient, Cushing's disease, Coronavirus, Disorder, Magnetic resonance imaging, Adrenal insufficiency, Technology, Industry, Health care, Mass spectrometry, Diagnosis, Awareness, Hyperthyroidism, Hormone, Prevalence, Laboratory, COVID-19, LC-MS, MRI, PET, Gigantism, RAI, CT, Hyperglycemia, FNA, Growth, Hypothyroidism, Pharmaceutical industry, Potash

Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders.

Key Points: 
  • Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders.
  • Key Questions Answered in This Report:
    How has the global endocrine testing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global endocrine testing market?
  • What is the structure of the global endocrine testing market and who are the key players?

$16+ Billion Worldwide Drugs For Hormonal Replacement Therapy Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Jeudi, novembre 11, 2021
General Health, Pharmaceutical, Health, Benchmark, Menopause, Population, Nausea, Hormone, Pharmacy, HGH, Female, Industry, Vaginal bleeding, European Menopause and Andropause Society, Estradiol (medication), Extrapyramidal system, Ageing, International Menopause Society, Coronavirus, Bloating, Growth, Vagina, Thrombus, Estrogen patch, Personal lubricant, Hypogonadism, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Kent, Woman, Stomach, Cardiovascular disease, HRT, Novo Nordisk, Create, Hypothyroidism, Breast cancer, Male, EMAS, Osteoporosis, Indigestion, Marketing, Birth control

Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.

Key Points: 
  • Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.
  • Thus, the increasing side effects of drugs hinders the growth of drugs for hormonal replacement therapy.
  • Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth.
  • Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market.

Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

Retrieved on: 
Mercredi, novembre 10, 2021
General Health, Medical Devices, Health, Pharmaceutical, Medical Supplies, NDA, Neutralizing antibody, Oxford, Neurology, EIH, Industry, Director, Glucagon, SG, Gastroenterology, Growth, COVID-19, SC, Silicon, Acquisition, Access, Temperature, Review, Communication, European Economic Area, PFS, Total, Safety, Glucagon (medication), Person, MBA, Failure, Conference, Research, Nature, FDA, Private Securities Litigation Reform Act, R, Senior management, CEO, Hypoglycemia, Doctor of Philosophy, Silicon Valley Bank, Twitter, Endocrinology, Prescription, Hypothyroidism, SEC, Pharmacokinetics, Avenue, Engineering, Merck, Investment, Instagram, Annual report, Perception, Board, Shanda, Company, LinkedIn, PDUFA, Nasdaq, IND, Pharmaceutical industry, Fine chemical, Bank, Cryptocurrency

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, and Xeris Pharmaceuticals, Inc., today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021.

Key Points: 
  • Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, and Xeris Pharmaceuticals, Inc., today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021.
  • Gvoke: Third quarter 2021 prescriptions topped 27,000 for the first time, growing more than 28% from the prior quarter and 95% compared to the same period in 2020.
  • Keveyis: Third quarter 2021 net sales of $11.5 million represent a 42% increase in revenue compared to $8.1 million during third quarter 2020.
  • Xeris will host a conference call and webcast today, Wednesday, November 10, 2021, at 8:30 a.m. Eastern Time.

Online Canadian Pharmacies Benefitting Americans Without Insurance

Retrieved on: 
Jeudi, octobre 21, 2021
Pharmacy, CIPA, Industry, Hypertension, OR, Plasma protein binding, Prescription, Medicare Part D, Medicare, Diabetes, Hypothyroidism, CDC, GLOBE, Population, Health insurance

Many of the drugs needed to manage diabetes, hypertension, hypothyroidism and other conditions are expensive, but an online Canadian pharmacy like Canada Pharmacy can provide the savings people need.

Key Points: 
  • Many of the drugs needed to manage diabetes, hypertension, hypothyroidism and other conditions are expensive, but an online Canadian pharmacy like Canada Pharmacy can provide the savings people need.
  • There is more to it than that, but the only big-picture understanding that many Americans - ones with OR without health insurance - may want to know is they can pay less for drugs, and if ordering from online Canadian pharmacies is the best way to do that.
  • Americans without health insurance are encouraged to look into what they would pay ordering their medication from Canada.
  • Canada Pharmacy is a Canadian online pharmacy among those recommended for Americans who shop at a pharmacy in Canada to save money on medications.

New Study Confirms That A Commonly Used Acid-Reducing Drug Does Not Interfere with the Absorption of A Novel Liquid Levothyroxine Formulation

Retrieved on: 
Lundi, octobre 4, 2021
Drug, Tablet, Hypothyroidism, Degenerative disease, Patient, Thyroid, Fatigue, Hair loss, Glycerol, Health, Water, FDA, Depression, GJ, Omeprazole, Constipation, Annual general meeting, Population, TSH, FT4, Thyroid disease, PPI, THE, Virginia Commonwealth University, University, Program, Arch, Internal medicine, Woman, Plasma protein binding, Medicine, Stomach, Absorption, ATA, Forgetting, Weight gain, Health care, Mouth, Cramp, American Thyroid Association, FT3, University of Pisa, IBSA, Pharmaceutical industry

Omeprazole and other PPI medications are powerful acid-reducing agents that are known to affect the performance of traditional levothyroxine treatments that come in tablet form.

Key Points: 
  • Omeprazole and other PPI medications are powerful acid-reducing agents that are known to affect the performance of traditional levothyroxine treatments that come in tablet form.
  • A second group was administered Tirosint-SOL and omeprazole at staggered times Tirosint-SOL in the morning and omeprazole in the evening, 12 hours later.
  • Based on these findings, IBSA Institut Biochimique, the sponsor of the study, is planning to seek FDA approval for a change in the approved label for Tirosint-SOL.
  • 46
    4.Canaris GJ, Manowitz NR, Mayor G, Ridgeway EC, "The Colorado Thyroid Disease Prevalence Study", Arch of Internal Medicine; 2000;160: 526-534
    5.McDermott MT.

BioInnovation Institute launches Venture Lab program with intake of innovative early-stage companies

Retrieved on: 
Mardi, septembre 14, 2021
Global health, Immunotherapy, Cancer, Artificial intelligence, Acceleration, Taste, Quality of life, 3D, Technology, Commit, Patient, HEI, Hypothyroidism, Aarhus University, Microtechnology, Novo Nordisk Foundation, Mortality, Disease, BII, Therapy, Environment, Solution, Skin, English brewery cask units, Food, EUR, Person, Liver disease, Human, Research, Life, Ecology, Bice, Pharmaceutical industry, Management, Medical imaging, Vaccine, Fine chemical

COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces the first cohort of participants in the Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces the first cohort of participants in the Venture Lab acceleration program for early-stage companies.
  • The new ventures BII has accepted into the Venture Lab program are the following:
    FLASH diagnostics: developing cutting-edge microscopy for use in the clinical diagnosis of cancer patients.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.
  • Since the inauguration of BII in November 2018, BII has awarded 35 million euros to 68 high-growth start-up companies.